Blastic plasmacytoid dendritic cell neoplasm: A clinicopathologic review

Yang Shi, Endi Wang

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

• Blastic plasmacytoid dendritic cell neoplasm is a rare entity grouped with the acute myeloid leukemia-related precursor neoplasms in the 2008 World Health Organization classification. It was previously postulated to originate from natural killer cells, T cells, or monocytes but is now believed to arise from the plasmacytoid dendritic cell. The pathogenesis of blastic plasmacytoid dendritic cell neoplasm is not well understood, although the neoplasm demonstrates frequent deletion of tumor suppressor genes, including RB1, CDKN1B, CDKN2A, and TP53. Blastic plasmacytoid dendritic cell neoplasm is a clinically aggressive tumor that often initially presents as cutaneous lesions and subsequently progresses to bone marrow involvement and leukemic dissemination. It is characterized by enhanced expression of CD56, CD4, and CD123, which can be detected by flow cytometry/immunohistochemistry. The differential diagnoses include myeloid sarcoma/acute myeloid leukemia, T-cell lymphoblastic leukemia/lymphoma, NK-cell lymphoma/leukemia, and some mature T-cell lymphomas/leukemias. Patients usually respond to initial chemotherapy but often relapse. Stem cell transplant may improve survival.

Original languageEnglish (US)
Pages (from-to)564-569
Number of pages6
JournalArchives of Pathology and Laboratory Medicine
Volume138
Issue number4
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Dendritic Cells
T-Cell Leukemia
Neoplasms
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
Natural Killer Cells
Myeloid Sarcoma
T-Cell Lymphoma
Tumor Suppressor Genes
Monocytes
Lymphoma
Flow Cytometry
Leukemia
Differential Diagnosis
Stem Cells
Bone Marrow
Immunohistochemistry
T-Lymphocytes
Transplants
Recurrence

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Cite this

Blastic plasmacytoid dendritic cell neoplasm : A clinicopathologic review. / Shi, Yang; Wang, Endi.

In: Archives of Pathology and Laboratory Medicine, Vol. 138, No. 4, 2014, p. 564-569.

Research output: Contribution to journalArticle

@article{d0d7f510d7dd4e52b6fed118a0087629,
title = "Blastic plasmacytoid dendritic cell neoplasm: A clinicopathologic review",
abstract = "• Blastic plasmacytoid dendritic cell neoplasm is a rare entity grouped with the acute myeloid leukemia-related precursor neoplasms in the 2008 World Health Organization classification. It was previously postulated to originate from natural killer cells, T cells, or monocytes but is now believed to arise from the plasmacytoid dendritic cell. The pathogenesis of blastic plasmacytoid dendritic cell neoplasm is not well understood, although the neoplasm demonstrates frequent deletion of tumor suppressor genes, including RB1, CDKN1B, CDKN2A, and TP53. Blastic plasmacytoid dendritic cell neoplasm is a clinically aggressive tumor that often initially presents as cutaneous lesions and subsequently progresses to bone marrow involvement and leukemic dissemination. It is characterized by enhanced expression of CD56, CD4, and CD123, which can be detected by flow cytometry/immunohistochemistry. The differential diagnoses include myeloid sarcoma/acute myeloid leukemia, T-cell lymphoblastic leukemia/lymphoma, NK-cell lymphoma/leukemia, and some mature T-cell lymphomas/leukemias. Patients usually respond to initial chemotherapy but often relapse. Stem cell transplant may improve survival.",
author = "Yang Shi and Endi Wang",
year = "2014",
doi = "10.5858/arpa.2013-0101-RS",
language = "English (US)",
volume = "138",
pages = "564--569",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "4",

}

TY - JOUR

T1 - Blastic plasmacytoid dendritic cell neoplasm

T2 - A clinicopathologic review

AU - Shi, Yang

AU - Wang, Endi

PY - 2014

Y1 - 2014

N2 - • Blastic plasmacytoid dendritic cell neoplasm is a rare entity grouped with the acute myeloid leukemia-related precursor neoplasms in the 2008 World Health Organization classification. It was previously postulated to originate from natural killer cells, T cells, or monocytes but is now believed to arise from the plasmacytoid dendritic cell. The pathogenesis of blastic plasmacytoid dendritic cell neoplasm is not well understood, although the neoplasm demonstrates frequent deletion of tumor suppressor genes, including RB1, CDKN1B, CDKN2A, and TP53. Blastic plasmacytoid dendritic cell neoplasm is a clinically aggressive tumor that often initially presents as cutaneous lesions and subsequently progresses to bone marrow involvement and leukemic dissemination. It is characterized by enhanced expression of CD56, CD4, and CD123, which can be detected by flow cytometry/immunohistochemistry. The differential diagnoses include myeloid sarcoma/acute myeloid leukemia, T-cell lymphoblastic leukemia/lymphoma, NK-cell lymphoma/leukemia, and some mature T-cell lymphomas/leukemias. Patients usually respond to initial chemotherapy but often relapse. Stem cell transplant may improve survival.

AB - • Blastic plasmacytoid dendritic cell neoplasm is a rare entity grouped with the acute myeloid leukemia-related precursor neoplasms in the 2008 World Health Organization classification. It was previously postulated to originate from natural killer cells, T cells, or monocytes but is now believed to arise from the plasmacytoid dendritic cell. The pathogenesis of blastic plasmacytoid dendritic cell neoplasm is not well understood, although the neoplasm demonstrates frequent deletion of tumor suppressor genes, including RB1, CDKN1B, CDKN2A, and TP53. Blastic plasmacytoid dendritic cell neoplasm is a clinically aggressive tumor that often initially presents as cutaneous lesions and subsequently progresses to bone marrow involvement and leukemic dissemination. It is characterized by enhanced expression of CD56, CD4, and CD123, which can be detected by flow cytometry/immunohistochemistry. The differential diagnoses include myeloid sarcoma/acute myeloid leukemia, T-cell lymphoblastic leukemia/lymphoma, NK-cell lymphoma/leukemia, and some mature T-cell lymphomas/leukemias. Patients usually respond to initial chemotherapy but often relapse. Stem cell transplant may improve survival.

UR - http://www.scopus.com/inward/record.url?scp=84898467743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898467743&partnerID=8YFLogxK

U2 - 10.5858/arpa.2013-0101-RS

DO - 10.5858/arpa.2013-0101-RS

M3 - Article

C2 - 24678689

AN - SCOPUS:84898467743

VL - 138

SP - 564

EP - 569

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 4

ER -